Background: Drug-resistant tuberculosis (DR-TB) is considered a real threat to the achievement of TB control. Testing of mycobacterial culture and testing of drug susceptibility (DST) capacity are limited in resource-poor countries, therefore inadequate treatment may occur, favouring resistance development. We evaluated the molecular assay GenoType ® MTBDRplus (Hain Lifescience, Germany) in order to detect DR-TB directly in clinical specimens as a means of providing a more accurate management of chronic TB patients in Burkina Faso, a country with a high TB-HIV co-infection prevalence.
Background
Emergence of drug-resistant Mycobacterium tuberculosis (MTB) strains is considered a real threat to achieving tuberculosis (TB) control [1] [2] [3] . Furthermore, multidrugresistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) require prolonged and expensive chemotherapy, with a decreased cure rate [4] [5] [6] .
As diagnosis of MDR-and XDR-TB is based on mycobacterial culture and drug susceptibility testing (DST) on liquid or solid media -with results available within weeks to months [7] [8] [9] -inadequate treatment as well as further spread of resistant strains and development of superresistance are likely to occur. Furthermore, standardized and optimised MTB culture and DST procedures require equipped, safe laboratories and trained human resources operating under quality assurance protocols. For all of these reasons, mycobacterial culture and DST capabilities are severely limited in resource-poor countries.
In response to the growing problem of MDR-TB and the threat of an epidemic of XDR-TB, the STOP TB strategy has been revised to include universal access to diagnosis and treatment for all patients with MDR-TB by 2015 [10, 11] . This plan calls for accelerated access to rapid testing for rifampin (RIF) resistance in order to improve case detection in all patients with suspected MDR-and XDR-TB. To ensure universal access, new technologies for rapid detection of anti-TB drug resistance in MTB have become a priority, especially in settings with high HIV-prevalence [12] [13] [14] [15] . Early detection of MDR-TB and XDR-TB is critical to initiating appropriate treatment, reducing morbidity and mortality, and preventing further transmission of drugresistant MTB strains.
Although rapid molecular methods are available for detecting drug-resistant TB [13, 14, 16] , the feasibility and cost-effectiveness of large-scale implementation in highburden low-income settings need to be assessed.
Demonstration projects on the GenoType ® MTBDRplus assay (Hain Lifesciences GmbH, Nehren, Germany), a polymerase chain reaction (PCR) amplification and reverse hybridization assay which detects RIF and isoniazid (INH) resistance, have been conducted in a high-burden low-income country [17] . This assay detects mutations in the rpoB gene for RIF resistance, and in both the katG gene and the promoter region of the inhA gene for INH resistance, directly from smear-positive sputum within one day [18] .
We evaluated the GenoType ® MTBDRplus, a reverse hybridization line probe assay for which detects DR-TB directly in clinical specimens as a means to provide with the purpose of providing more effective management of chronic TB patients in Burkina Faso, a country with a high TB-HIV co-infection prevalence [19] .
Methods

Study settings
Samples were collected in Burkina Faso, a country in West Africa with an estimated population of 14.9 million, and an estimated incidence of TB (all forms) of 248/100.000 [19] . In 2008, the prevalence of HIV infection in TB patients in Burkina Faso was 12.4% with a prevalence of HIV among adult population estimated to be 1.6% [20, 21] .
Culture and DST are not currently available in Burkina Faso and chronic TB cases are classified and treated based on clinical evaluation and sputum smear microscopy results.
The work described in this paper was performed in the framework of the agreement for technical support requested by the National Tuberculosis Programme (NTP) of Burkina Faso (responsible body for TB management in the Country) to the Supranational Reference at the San Raffaele Institute, Milan, Italy and the University of Brescia, Italy. The NTP of Burkina Faso didn't consider ethical approval to be necessary since this action was recommended by the Green Light Committee in order to provide better management to chronic TB patients. All patients were informed and consented to the study with the local physicians.
The NTP has now prioritized the establishment of culture and DST facilities by 2009 and rapid testing by 2010.
Clinical samples
One hundred and eight patients who met the definition of "chronic pulmonary TB" ("patient who remained sputum smear-positive after completing a re-treatment regimen for pulmonary TB under Directly Observed Therapy (DOT)", [22] ) were started on a second line drug regimen using a standardised treatment strategy (Category IV) [23] . The Category IV drug regimen used in Burkina Faso consists of kanamycin, ofloxacin, ethionamide, pyrazinamide and cycloserine for six months, followed by 15 months of ofloxacin, ethionamide and cycloserin.
Patients were enrolled at the two centres for chronic TB patient management in Burkina Faso (Ouagadougou and Bobo-Dioulasso) from December 2006 to October 2008. Sixty-one patients were enrolled at the beginning of a Category IV regimen (Month 0, M0). Forty-seven patients were enrolled at variable times during their Category IV therapy. Twenty-six out the 47 patients enrolled during treatment follow-up were already classified as smear-negative ( Figure 1 ). Two early morning sputum samples were collected from each patient at enrolment into the study, immediately frozen and shipped to Italy in dry ice.
Upon arrival, samples were decontaminated and processed for smear microscopy and DNA extraction. Culture was attempted on MGIT960 (Becton Dickinson, Cockeysville, USA) automated system in agreement with the manufacturer's instructions.
Molecular DST
Decontaminated specimens were analyzed for presence of mutations conferring resistance to RIF and INH by the molecular assay GenoType ® MTBDRplus.
DNA from decontaminated clinical specimens was extracted by thermal lysis and sonication and GenoType ® MTBDRplus assay was performed in accordance with the manufacture's instructions with minor modifications (as specified below). In brief, 500 μL of decontaminated sample were centrifuged at 13000 rpm at 4°C for 15 minutes; pellet was resuspended in 75 μL of sterile distilled water and mycobacteria were lysed by incubation at 95°C for 30 minutes and sonication for 15 minutes. Five microliters of lysate were used for amplification with the provided biotinylated primers. Two units (instead of 1 as reported in manufacturer's instructions) of hot-start Taq DNA polymerase were used in the amplification step. The amplification was performed in a BioRad iCycler (BioRad, Hercules, CA) thermal cycler with a protocol consisting of 1 cycle at 95°C for 15 min (Taq activation cycle), 10 cycles of denaturation at 95°C for 30 sec and primer annealing at 58°C for 2 min, 40 cycles of denaturation at 95°C for 25 sec, primer annealing at 53°C for 40 sec and extension at 70°C for 40 sec, followed by a final extension at 70°C for 8 min.
The GenoType ® MTBDRplus is based on reverse hybridization between amplicons derived from a multiplex PCR and nitrocellulose-bound wild-type (WT) and mutated (MUT) probes targeting the hotspot region of rpoB gene, the codon 315 of katG gene and the promoter region of inhA gene. The assay also includes amplification controls for each targeted gene, an additional probes for gram-positive GC rich organisms, and a control-probe for MTB complex DNA detection. Hybridisation and washing were performed manually using the TWINCUBATOR ® HybridiCulture and GenoType ® MTBDRplus results in patients enrolled at different times under category IV regimens zation Tray (Hain Lifesciences, Nehren, Germany). Strips were interpreted for susceptibility or resistance to RIF and INH according to manufacturer's instructions.
Results
The GenoType ® MTBDRplus test was performed on all samples regardless of the sputum smear results. Twentyone samples out of the 61 enrolled at M0 were not reconfirmed as sputum smear-positive ( Figure 1 ). We obtained a valid test result (based on the hybridisation of the internal controls of the assay) in 60/61 smear-positive and 47/ 47 smear-negative samples ( 
Sputum smear-negative samples analysis
Despite the fact that we did not re-confirm as smear-positive 21 patients enrolled at M0, we included these samples in the molecular analysis. Twenty-six patients enrolled during therapy and resulting smear-negative were also included in the study ( Concerning INH resistance, all cases identified by the molecular assay (n 33) were carrying a S315T substitution in katG gene. In 39.4% (13/33) of cases, a mutation affecting the promoter region of inhA gene was also detected. Observed frequency of mutation in this region was 21.2% (7/33) t-8c, 12.1% (4/33) t-8a, and 6.1% (2/33) c-15t, respectively. In 20 out of 33 cases (60.6%) no mutation was identified in the promoter region of inhA gene.
Frequency of mutations observed in sputum smear-negative samples are also reported in Table 2 .
Discussion
Conventional methods for mycobacteriological culture and DST are slow and labour intensive, requiring sequential procedures for isolation of mycobacteria from clinical specimens, identification of MTB complex, and in vitro testing of strain susceptibility to anti-TB drugs. During this time patients may be prescribed inadequate treatment, thus fuelling the development and/or spread of drug resistance. Novel technologies for rapid detection of anti-TB drug resistance have therefore become a priority in TB research and development, and molecular line probe assays focused on rapid detection of RIF resistance (alone or in combination with INH) are now commercially available.
In June 2008, concomitantly with the first published meta-analysis on MTBDR line probe assays [24] , WHO has made public the policy statement on molecular line probe assays for rapid screening of patients at risk of MDR-TB [25] . However, adoption of line probe assays does not eliminate the need for conventional culture and DST capability, as culture remains necessary for definitive diagnosis of TB in sputum smear-negative patients, while conventional DST of second line drugs is required to diag-nose XDR-TB. Moreover, culture and DST are still essential for patient follow-up during treatment.
The aim of our study was to evaluate the molecular assay GenoType ® MTBDRplus for detecting DR-TB directly in sputum specimens as a means to provide a more accurate management of chronic TB patients in Burkina Faso. Our study demonstrates that the GenoType ® MTBDRplus assay can be used to identify MDR-TB cases correctly in the absence of culture facilities in TB patients classified as "chronic" according to internationally accepted criteria. Moreover, this study strongly suggests that sputum smearmicroscopy as the only criteria to identify chronic TB patients is inadequate because of the risk of false positives.
The use of the GenoType ® MTBDRplus molecular test, with further confirmation from culture and DST, allowed readjustment of patients' treatment in over half of the cases studied: 1) patients who were classified and treated as MDR-TB cases harbouring RIF-and INH-S strains (n 24); 2) patients negative for MTB complex DNA among those enrolled at M0 or remaining smear-positive during follow-up (n 24); 3) patients with a NTM infection (n 13). In addition, the correct classification of patients allowed to reconsider their need for hospitalization in MDR-TB wards limiting nosocomial exposure to MDR-TB.
The GenoType ® MTBDR plus assay performed directly on clinical specimens is less expensive than culture-based DST. We recommend that cost-effectiveness in applying the test should be carefully evaluated in each setting taking into account specific situations (e.g. TB and HIV prevalence), technical skills available on site, and frequency of mutations among resistant samples to evaluate the sensitivity of the molecular assay.
More data is needed to validate the use of molecular assays for rapid detection of drug resistance to key anti-TB drugs such as RIF and INH under routine conditions.
Our study found that the GenoType ® MTBDR plus yielded interpretable results in more than 99% of the cases, among both smear-positive and smear-negative sputum samples.
Reported sensitivities for RIF-and INH-resistance for the GenoType ® MTBDR plus are ≥ 97% and ≥ 90%, respectively [24] . Also specificities are accounted to be ≥ 99% for both RIF-and INH-resistances. In our study, 4 samples showed INH susceptibility by molecular line probe assay, while these were identified as INH-resistant by culture based DST. A possible explanation is the lower sensitivity of the test on INH resistance since the GenoType ® MTBDR plus targets only 2 of the several genomic regions involved in determining INH-resistance [26] .
Three samples designated as MDR-TB by GenoType ® MTBDR plus assay, were not confirmed to be RIF resistant on culture-based DST. Further investigation on these 3 cases identified mutations in the rpoB gene (M515I+H526N, L533P, and H526N respectively). Discrepancies between culture and molecular DST can be interpreted by studying the MICs of the corresponding strains. In fact, strains carrying the substitution L533P in rpoB gene have been demonstrated to have different MIC values (from 0.5-1.0 μg/mL up to 32 μg/mL) [27, 28] . Further evaluation on the three strains carrying substitutions in rpoB gene allowed to identify increased MIC values.
Our study had several limitations. Discrepant results in sputum smear microscopy in Burkina Faso and Italy could be due to differences in the sampling time and in recruitment of patients by peripheral centers with suboptimal capacity in smear microscopy.
Discrepant GenoType ® MTBDRplus-positive and culturenegative samples may be justified in two ways. First, some samples were collected and transported to Italy under suboptimal conditions and this may have affected their culture results [29] . Second, most of the culture-negative samples harboured DNA from MTB susceptible strains by GenoType ® MTBDRplus. For these cases we speculate that standard TB treatment was effective and prescription of WHO Category IV regimen unnecessary.
One case with negative culture and with a positive MDR profile on molecular assay may be due to the fact that this case was sampled six months after the beginning of the therapy with category IV regimen. In fact, we observed during treatment follow-up that the molecular assay became negative between month 3 and month 6 in patients under effective treatment (data not shown).
Two sputum smear-negative samples harbouring NTM (M. intracellulare, M. avium) were identified as MTB complex positive by the GenoType ® MTBDRplus. This may be due to successful treatment that contributed to select microorganisms not belonging to the MTB complex.
Results obtained in our sample suggest that in Burkina Faso the frequency of mutations involved in RIF resistance differs from that of other settings. The commonest mutation is the D516V substitution in the hotspot region of rpoB gene, detected entirely in 43.8% (14/32) of RIF resistant cases. The S531L mutation is responsible of resistant phenotype in only 9.4% (3/32) in our study, whereas this substitution affects the majority of RIF resistant strains in most of other countries worldwide [26] . In this study we observed that mutations in the promoter region of inhA gene had a minor role in conferring resistance to INH. As these data were obtained from chronic patients undergoing two cycles of standard first-line drugs regimen, we believe that low-level resistance mutations have favoured secondary selections for high-level resistance mutations such as S315T substitution in the katG gene [30] , and we recommend further studies be conducted.
The molecular test correctly identifies as MTB-complex negative all the patients in which the smear positivity was probably due to the presence of NTMs as suggested by culture results. The addition of a Mycobacteria genus specific probe could address this problem improving the clinical usefulness of the test, especially in high HIV prevalence settings.
As shown in other studies the molecular assay has been successfully performed on contaminated cultures to obtain drug susceptibility data [17] . This provides important drug resistance data in settings where culture and culture DST testing are not conducted correctly as confirmed by quality control systems.
Conclusion
In conclusion, our results demonstrate the usefulness of the GenoType ® MTBDR plus assay in identifying MDR-TB cases (among patients satisfying the chronic TB definition), in the absence of culture facilities. The molecular assay improved the management of chronic cases by offering timely access to more appropriate anti-TB regimens, and this could limit the emergence of resistance due to the misuse of antibiotics, and reduce public health expenses. Guidelines and algorithms for line probe assays use should be available to improve quality and cost-effective use of molecular assays in TB control, and be specifically evaluated in local settings. We recommend that an external quality assurance system should exist for all laboratories performing the test.
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